Prophylaxis of Thrombembolism

Aus coViki
Wechseln zu: Navigation, Suche

prophylaxis and treatment of thombembolic disorders

  • GET ä. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Extract
  • GET ä. Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies Extract
  • GET ä. Hospital-based use of thromboprophylaxis in patients with COVID-19 Extract
  • GET ä. Where do we stand with antithrombotic prophylaxis in patients with COVID-19? Extract
  • GET 2020. COVID-19 and its implications for thrombosis and anticoagulation Extract
  • GET 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action Extract
  • GET 2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients Extract
  • GET 2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend Extract
  • GET 2020. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2 Extract
  • GET 2020. The versatile heparin in COVID-19 Extract
  • GET 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Extract
  • GET 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment Extract
  • GET 2020. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19 Extract
  • GET 2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Extract
  • GET 2020. Response to Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Extract
GET 2020. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience Extract
  • GET 2020. Type and dose of heparin in Covid-19: Reply Extract
  • GET 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19 Extract
  • GET 2020. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis Extract
  • GET 2020. DOACs and newer haemophilia therapies in COVID-19 Extract
  • GET 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? Extract
  • GET 2020. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge Extract
  • GET 2020. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Extract
  • GET 2020. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines Extract
  • GET 2020. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series Extract
  • GET ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment Extract
GET ä. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 Extract
  • GET ä. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19 Extract
  • GET 2020. Potential of heparin and nafamostat combination therapy for COVID-19 Extract
  • GET ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients Extract
  • GET ä. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 Extract
  • GET 2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 Extract
  • GET 2020. Prevention of thrombosis in pregnant women with suspected SARS-CoV-2 infection: clinical management algorithm. Extract
  • GET 2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities. Extract
  • GET ä. Anticoagulation in COVID-19 Extract
GET 2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 Extract
  • GET ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment Extract
  • GET ä. Recomendaciones sobre el tratamiento antitrombotico durante la pandemia COVID-19 Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espanola de Cardiologia Extract
  • GET 2020. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis Extract
  • GET 2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial". Extract
  • GET 2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge